Article Sidebar
Published:
Sep 10, 2014Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Preliminary Investigation of Risk Factors Causing Dyskinesias in Parkinson’s Disease in South Africa
Abstract
Purpose: To determine the risk factors involved in the onset of dyskinesias in patients suffering from Parkinson’s disease in South Africa.
Methods: A questionnaire survey and medical record review were conducted. A total of 43 patients with Parkinson’s disease in two metropolitan areas were included in the study.
Results: The number of patients with dyskinesias indicated by medical records (n =10) was less than the number of patients with self-reported dyskinesias (n = 13). According to the patient interviews, the mean prescribed daily dose (PDD) of levodopa was 750 ± 452 mg. Twelve patients had been using levodopa for > 10 years. Mean PDD of levodopa according to the medical records was 809 ± 514 mg, with dyskinetic patients receiving a higher average PDD of 870 ± 590 mg. Half of the patients with dyskinesias were diagnosed more than 10 years ago. Patients with dyskinesias were diagnosed with Parkinson’s disease at a younger age (11.63 % dyskinetic patients were diagnosed between 40 and 60 years), and experienced longer disease duration. There were no gender differences (p = 0.80) in the incidence of dyskinesias.
Conclusion: Higher doses of levodopa, longer disease duration and a longer duration of levodopa therapy were risk factors for dyskinesias. Further studies are needed on the incidence of dyskinesias.
Keywords: Parkinson’s disease, Dyskinesias, Levodopa; Drug utilisation South Africa
